Safety Considerations with Fibrate Therapy
Top Cited Papers
- 19 March 2007
- journal article
- review article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 99 (6), S3-S18
- https://doi.org/10.1016/j.amjcard.2006.11.016
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiencyKidney International, 2004
- Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in HumansThe Journal of Clinical Pharmacology, 2004
- Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteineAmerican Heart Journal, 2003
- ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of StatinsStroke, 2002
- Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy VolunteersThe Journal of Clinical Pharmacology, 2000
- Lipid-lowering drugs and homocysteineThe Lancet, 1999
- The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐upJournal of Internal Medicine, 1994
- The Effect of Renal Function on the Pharmacokinetics of GemfibrozilThe Journal of Clinical Pharmacology, 1987
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaThe New England Journal of Medicine, 1987
- Untoward Effects of Clofibrate in Hemodialyzed PatientsThe New England Journal of Medicine, 1977